Immunocan
Latest round
- Series A
Last raised
- May 2026
Total raised
- $37M
Investors
- 4
About Immunocan
, trading as Immunocan, is a biotech company that focuses on creating a new antibody drug platform. The company engages in creating a new antibody drug platform. The company's gene editing and replacement technology can replace several Mb-level DNA fragments at a time. The company is developing antibody drugs for cancer patients. The company's revenue is generated by creating a new antibody drug platform.antibody drug screening platform, the development of backbone antibodies for complex targets, and the company's daily operations and team expansion.
Who invested in Immunocan
4 investors across 1 round
See all investors in Immunocan
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
May 13, 2026
Amount
$37M
Investors
Questions about Immunocan
Who invested in Immunocan?
Immunocan has 4 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Immunocan raised?
Immunocan has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Immunocan last raise money?
Immunocan's most recent round on record is a Series A, in May 2026.
What does Immunocan do?
, trading as Immunocan, is a biotech company that focuses on creating a new antibody drug platform.
Where is Immunocan headquartered?
Immunocan is headquartered in Shanghai, China.
Which VCs invest in companies like Immunocan?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Immunocan's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Immunocan? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.